Precursor Isoform of Prostate-Specific Antigen and Human Kallikrein 2: Two New Promising Biomarkers for the Unsolved Challenge of Early Prostate Cancer Detection

European Urology

Volumn 55, Issue 3, 2009, Pages 556-559

  Ficarra, Vincenzo ^a   Novara, Giacomo ^a   Galfano, Antonio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; KALLIKREIN 2; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

CANCER DIAGNOSIS; CANCER GRADING; CANCER RISK; CANCER SCREENING; CLINICAL PRACTICE; EDITORIAL; HUMAN; MEDICAL PRACTICE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; TUMOR BIOPSY;

BIOLOGICAL MARKERS; EARLY DETECTION OF CANCER; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTEIN PRECURSORS; TISSUE KALLIKREINS;

EID: 58849149806     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.12.018     Document Type: Editorial

References (23)

1. Crawford E.D., and Abrahamsson P.-A. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?. Eur Urol 54 (2008) 262-273
2. Gohagan J.K., Prorok P.C., Hayes R.B., and Kramer B.S. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial project team. The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials 21 6 Suppl (2000) 251S-272S
3. Schröder F.H., Denis L.J., and Roobol M. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 92 Suppl 2 (2003) 1-23
4. American Urological Association. Prostate-specific antigen (PSA) best practice policy. Oncology 14 (2000) 267-272
5. Smith R.A., Cokkinides V., and Eyre H.J. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin 56 (2006) 11-25
6. National Comprehensive Cancer Network. NCCN practice guidelines in oncology. Prostate cancer early detection. Available at http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf. Accessed July 11, 2007.
7. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
8. Boyle P. Screening for prostate cancer: have you had your cholesterol measured ?. BJU Int 92 (2003) 191-199
9. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
10. Bjartell A. PSA and prostate cancer screening: the challenge of the new millennium. Eur Urol 52 (2007) 1284-1286
11. Nadler R.B. The case for prostate-specific antigen screening starting at age 40. Cancer 113 (2008) 1278-1281
12. Loeb S., Roehl K.A., Antenor J.A., et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 67 (2006) 316-320
13. Loeb S., Roehl K.A., Catalona W.J., et al. Is the utility of prostate-specific antigen velocity for prostate cancer detection affected by age?. BJU Int 101 (2008) 817-821
14. Schröder F.H., Carter H.B., Wolters T., et al. Early detection of prostate cancer in 2007: part 1: PSA and PSA kinetics. Eur Urol 53 (2008) 468-477
15. Roddam A.W., Duffy M.J., Hamdy F.C., et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 48 (2005) 386-399
16. Walz J., Haese A., Scattoni V., et al. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. Cancer 113 (2008) 2695-2703
17. Steuber T., O'Brien M.F., and Lilja H. Serum markers for prostate cancer: a rational approach to the literature. Eur Urol 54 (2008) 31-40
18. Jansen F.H., Roobol M., Jenster G., Schröder F.H., and Bangma C.H. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol 55 (2009) 563-574
19. Pepe M.S., Etzioni R., Feng Z., et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93 (2001) 1054-1061
20. Parekh D.J., Ankerst D.P., Troyer D., Srivastava S., and Thompson I.M. Biomarkers for prostate cancer detection. J Urol 178 (2007) 2252-2259
21. Stenman U.H., Abrahamsson P.A., Aus G., et al. Prognostic value of serum markers for prostate cancer. Scand J Urol Nephrol 39 (2005) 64-81
22. Vickers A.J., Cronin A.M., Aus G., et al. A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden. BMC Medicine 6 (2008) 19
23. Haese A., de la Taille A., van Poppel H., et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54 (2008) 1081-1088